CD80 and cholangiocarcinoma: This pilot study revealed that IDO1, FASLG, CD80, HAVCR2, CD73, CTLA-4, LGALS9, VTCN1 and TNFRSF14 in combination with PD-L1 is linked with poor outcome in CCA patients.